SCOTUS’ abortion pill mifepristone case is really about the FDA
WASHINGTON — The Supreme Court on Tuesday will hear opening arguments in an abortion medication case that pharmaceutical companies warn could upend the industry and paralyze new drug development.
Industry players were initially reluctant to weigh in on the fate of mifepristone, approved by the Food and Drug Administration in 2000 for abortion up to seven weeks of pregnancy. The agency in 2016 extended that approval to 10 weeks and in 2021 removed the in-person dispensing requirement, citing years of data showing the drug’s relative safety. Now, in the wake of Roe v. Wade’s upheaval, both those later changes could be reversed after a Fifth Circuit Court of Appeals’ ruling.
Read Original Article: SCOTUS’ abortion pill mifepristone case is really about the FDA »
